Anlotinib Offers Efficacy Across Subtypes of Soft-Tissue Sarcoma

[JolieS]

I haven't heard of Anlotinib, but it looks like a promising TKI that has been in trials in China:

"With regard to STS subtypes, several appeared to derive more benefit from anlotinib than others: 69.2% of leiomyosarcoma patients were progression-free at 12 weeks, as were 76.92% of alveolar soft part sarcoma patients; several others also exceeded 60%. The ORR was highest in alveolar soft part sarcoma, at 46.15%. "

Article: http://www.cancernetwork.com/sarcoma/an ... ue-sarcoma

[Olga]

Thank you, I am moving it to the clinical trials. This is Chinese company testing its drug in China, with so far interesting activity in ASPS (durability of response and the problem with rebound are unknown as this is a trial).
https://clinicaltrials.gov/ct2/show/NCT ... ib&rank=11
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) ClinicalTrials.gov Identifier: NCT02449343

[cachabamba10]

I believe the CEO of the company behind this drug will be speaking at the ASPS day of learning at Miami. I read one report on facebook and my understanding was that there was only 2 significant responses from ASPS patients but I think I am wrong. I will do more research on this, also I wonder if we have access to this drug here in the USA. I will ask Dr. Benjamin about this drug and see what his thoughts are.

[D.ap]

This discussion was started by Jolie in 2016.
Clinical trials involving ASPS patients are being performed , as we speak .
I’d like to understand what’s being found to be true in the clinical trial successes .


https://jhoonline.biomedcentral.com/art ... 018-0664-7

http://www.cureasps.org/